



Contents lists available at ScienceDirect

Respiratory Medicine

journal homepage: www.elsevier.com/locate/rmed

Short communication

Current thinking and new paradigm for COPD

Tobias Welte ^{a,*}, Kenneth R. Chapman ^b, Helgo Magnussen ^c, Marc Miravittles ^d^a Department of Pulmonary Medicine, Hannover Medical School and Member of the German Center of Lung Research (DZL), Hannover, Germany^b Asthma and Airway Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada^c Pulmonary Research Institute at Lung Clinic Grosshansdorf, Grosshansdorf, Germany^d Department of Pneumology, Vall d'Hebron University Hospital, Barcelona, Spain

ARTICLE INFO

Article history:

Received 15 October 2015

Received in revised form

21 October 2015

Accepted 26 October 2015

Available online 13 January 2016

ABSTRACT

During the 2015 European Respiratory Society Congress, a symposium was held on 'Current thinking and new paradigm for COPD'. Through a combination of plenary lectures and interactive panel discussions, experts discussed the recent evidence for chronic obstructive pulmonary disease (COPD) treatment and how this evidence can be applied in clinical practice.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The aims of chronic obstructive pulmonary disease (COPD) treatment are to alleviate symptoms and reduce future risks. At the 'Current thinking and new paradigm for COPD' symposium, held on 28 September at the 2015 European Respiratory Society Congress in Amsterdam, The Netherlands, respiratory experts discussed how our current understanding of optimal treatment approaches and the potential future of COPD management can help physicians to meet these goals.

Through plenary lectures and interactive panel discussions, the expert faculty took delegates on a journey through the COPD treatment paradigm, highlighting current thinking and future perspectives in the field. They explored the rationale for combining classes of bronchodilators (the cornerstone of COPD treatment), and the efficacy and safety of dual bronchodilator combinations. The faculty also discussed the prevention of COPD exacerbations, including the benefits and risks associated with the use of inhaled corticosteroids in COPD management. Clinical evidence presented throughout the symposium was translated into real-life patient case studies, which reviewed how data from clinical trials can be applied in real-life practice. Key issues in COPD management were further explored during several lively panel discussions.

The full symposium can be viewed at the link provided below.

Financial support

Funding for the webcast and for medical writing support for the Webcast Report was provided by Novartis Pharma AG (Basel, Switzerland).

Conflict of interest

T. Welte: speaker for Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Mundipharma, Novartis, GlaxoSmithKline and Teva. He has received honoraria for attending advisory panels with AstraZeneca, Boehringer Ingelheim, Chiesi, MSD and Novartis, as well as receiving funding for research projects from Novartis.

K. Chapman: speaker for AstraZeneca, Boehringer Ingelheim, Grifols, GlaxoSmithKline, Merck Frosst, Novartis, Pfizer and Takeda. He has research grants/contracts with Almirall, Amgen, AstraZeneca, CSL Behring, Forest Labs, Genentech, GlaxoSmithKline, Grifols, Novartis, Nycomed, Roche, Schering and Takeda. He has received consulting fees from CSL Behring, GlaxoSmithKline, Grifols, Merck Frosst, Novartis, Nycomed, Pfizer, Roche and Schering Plough.

H. Magnussen: research collaborations with Almirall, Bayer, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, InterMune, Merck, Novartis, Takeda, Revotar, Roche and Pfizer. He has received honoraria for attending advisory panels with Almirall, Aerocrine, Berlin Chemie, Boehringer Ingelheim, AstraZeneca, Chiesi, Merck, Novartis, Takeda, Revotar and Roche.

* Corresponding author.

E-mail addresses: welte.tobias@mh-hannover.de (T. Welte), ken.chapman.airways@gmail.com (K.R. Chapman), magnussen@pulmoresearch.de (H. Magnussen), marcm@separ.es (M. Miravittles).

M. Miravittles: speaker for Almirall, AstraZeneca, Bayer Schering, Boehringer Ingelheim, Novartis, Pfizer, Talecris and Takeda-Nycomed. He has received consulting fees from Almirall, AstraZeneca, Bayer Schering, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer and Takeda-Nycomed.

Supplementary data

The webcast associated with this Webcast Report can be found, in the online version, at <http://respiratory-webcast.elsevierresource.com>.